Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.

Kaufer D, Gandy S.

Neurology. 2009 Dec 15;73(24):2052-3. doi: 10.1212/WNL.0b013e3181c6784a. Epub 2009 Nov 18. No abstract available.

PMID:
19923549
2.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators.

Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.

3.

Bapineuzumab.

Kerchner GA, Boxer AL.

Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi: 10.1517/14712598.2010.493872. Review.

4.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Laskowitz DT, Kolls BJ.

Neurology. 2010 Jun 15;74(24):2026; author reply 2026-7. doi: 10.1212/WNL.0b013e3181e03844. No abstract available.

PMID:
20548049
5.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

6.

Bapineuzumab in Alzheimer's disease: where now?

Wilcock GK.

Lancet Neurol. 2010 Feb;9(2):134-6. doi: 10.1016/S1474-4422(09)70359-X. No abstract available.

PMID:
20129159
7.

Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.

Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E.

J Alzheimers Dis. 2016;49(4):1123-34. doi: 10.3233/JAD-150448.

PMID:
26639957
8.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

9.

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators.

Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7.

10.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

PMID:
20189881
11.

Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy.

Greenberg SM, Frosch MP.

Neurology. 2011 Mar 1;76(9):772-3. doi: 10.1212/WNL.0b013e31820e7bce. No abstract available.

PMID:
21357829
12.

A single ascending dose study of bapineuzumab in patients with Alzheimer disease.

Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203. doi: 10.1097/WAD.0b013e3181c53b00.

13.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80. Review.

PMID:
21091109
14.

Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.

Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melançon D, Morris K, Ketter N, Liu E, Brashear HR.

J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):106-12. doi: 10.1136/jnnp-2014-309493. Epub 2015 Feb 10.

15.

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

Bouter Y, Lopez Noguerola JS, Tucholla P, Crespi GA, Parker MW, Wiltfang J, Miles LA, Bayer TA.

Acta Neuropathol. 2015 Nov;130(5):713-29.

PMID:
26467270
16.

Immunomodulation and AD--down but not out.

Knight EM, Gandy S.

J Clin Immunol. 2014 Jul;34 Suppl 1:S70-3. doi: 10.1007/s10875-014-0039-y. Epub 2014 Apr 30. Review.

PMID:
24781637
17.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.

Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H.

Mol Psychiatry. 2014 Feb;19(2):148-9. doi: 10.1038/mp.2013.18. Epub 2013 Feb 19. No abstract available.

18.

J&J's billion dollar punt on anti-amyloid antibody.

Sheridan C.

Nat Biotechnol. 2009 Aug;27(8):679-81. doi: 10.1038/nbt0809-679. No abstract available.

PMID:
19668155
19.

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

Panza F, Solfrizzi V, Imbimbo BP, Logroscino G.

Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30. Review.

PMID:
24981190
20.

Aβ amyloid, cognition, and APOE genotype in healthy older adults.

Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P; AIBL Research Group.

Alzheimers Dement. 2013 Sep;9(5):538-45. doi: 10.1016/j.jalz.2012.07.004. Epub 2012 Nov 14.

PMID:
23159043

Supplemental Content

Support Center